Physician profile
David S Garson
NPI 1457337388
$5,745.35
in general payments reported to CMS, 2019-2025
33 companies · $1,370 in 2025
The $1,370 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $204 · 2021: $154 · 2022: $912 · 2023: $1,030 · 2024: $1,069 · 2025: $1,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,439 · Education: $30.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,438.88 |
| Education | $30.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,073.63 | 2019-2025 | |
| Janssen Biotech, INC. | $856.65 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $550.17 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $342.71 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Cook Medical LLC | $307.89 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.74 | 2019-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $171.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $166.82 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $105.82 | 2024-2025 | Dupixent |
| Celgene Corporation | $94.45 | 2022-2024 | Zeposia |
| Genzyme Corporation | $85.13 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $67.63 | 2019-2023 | Linzess |
| Phathom Pharmaceuticals, INC. | $66.17 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $61.10 | 2019-2024 | |
| Allergan, INC. | $45.00 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $42.77 | 2022-2025 | Sucraid |
| Gilead Sciences, INC. | $42.49 | 2025 | |
| Aimmune Therapeutics, INC. | $39.28 | 2024-2025 | Vowst |
| Braintree Laboratories, INC. | $38.85 | 2019-2020 | |
| Alfasigma USA, INC. | $37.34 | 2022 | |
| Organon LLC | $30.77 | 2023 | Renflexis, Hadlima |
| Daiichi Sankyo INC. | $29.83 | 2019-2023 | Injectafer |
| Fujifilm Healthcare Americas Corporation | $23.80 | 2022 | |
| Redhill Biopharma INC. | $23.76 | 2020 | |
| Sandoz INC. | $23.21 | 2023 | Hyrimoz |
| Ferring Pharmaceuticals INC. | $20.97 | 2023 | Rebyota |
| Nestle Healthcare Nutrition INC. | $20.40 | 2023 | |
| Concordia Pharmaceuticals INC. | $20.22 | 2019 | |
| Celltrion USA INC. | $20.07 | 2024 | Zymfentra |
| Ipsen Biopharmaceuticals, INC | $18.00 | 2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $17.41 | 2023 | Terlivaz |
| Dova Pharmaceuticals | $16.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Garson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.